Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA
We assessed video directly observed therapy (VDOT) for monitoring tuberculosis treatment in 5 health districts in California, USA, to compare adherence between 274 patients using VDOT and 159 patients using in-person directly observed therapy (DOT). Multivariable linear regression analyses identifie...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Centers for Disease Control and Prevention
2018-10-01
|
| Series: | Emerging Infectious Diseases |
| Subjects: | |
| Online Access: | https://wwwnc.cdc.gov/eid/article/24/10/18-0459_article |
| _version_ | 1818693132222464000 |
|---|---|
| author | Richard S. Garfein Lin Liu Jazmine Cuevas-Mota Kelly Collins Fatima Muñoz Donald G. Catanzaro Kathleen Moser Julie Higashi Teeb Al-Samarrai Paula Kriner Julie Vaishampayan Javier Cepeda Michelle A. Bulterys Natasha K. Martin Phillip Rios Fredric Raab |
| author_facet | Richard S. Garfein Lin Liu Jazmine Cuevas-Mota Kelly Collins Fatima Muñoz Donald G. Catanzaro Kathleen Moser Julie Higashi Teeb Al-Samarrai Paula Kriner Julie Vaishampayan Javier Cepeda Michelle A. Bulterys Natasha K. Martin Phillip Rios Fredric Raab |
| author_sort | Richard S. Garfein |
| collection | DOAJ |
| description | We assessed video directly observed therapy (VDOT) for monitoring tuberculosis treatment in 5 health districts in California, USA, to compare adherence between 274 patients using VDOT and 159 patients using in-person directly observed therapy (DOT). Multivariable linear regression analyses identified participant-reported sociodemographics, risk behaviors, and treatment experience associated with adherence. Median participant age was 44 (range 18–87) years; 61% of participants were male. Median fraction of expected doses observed (FEDO) among VDOT participants was higher (93.0% [interquartile range (IQR) 83.4%–97.1%]) than among patients receiving DOT (66.4% [IQR 55.1%–89.3%]). Most participants (96%) would recommend VDOT to others; 90% preferred VDOT over DOT. Lower FEDO was independently associated with US or Mexico birth, shorter VDOT duration, finding VDOT difficult, frequently taking medications while away from home, and having video-recording problems (p<0.05). VDOT cost 32% (range 6%–46%) less than DOT. VDOT was feasible, acceptable, and achieved high adherence at lower cost than DOT. |
| first_indexed | 2024-12-17T13:08:49Z |
| format | Article |
| id | doaj.art-45d87979af584eb0aeea74e82ea980e9 |
| institution | Directory Open Access Journal |
| issn | 1080-6040 1080-6059 |
| language | English |
| last_indexed | 2024-12-17T13:08:49Z |
| publishDate | 2018-10-01 |
| publisher | Centers for Disease Control and Prevention |
| record_format | Article |
| series | Emerging Infectious Diseases |
| spelling | doaj.art-45d87979af584eb0aeea74e82ea980e92022-12-21T21:47:11ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592018-10-0124101806181510.3201/eid2410.180459Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USARichard S. GarfeinLin LiuJazmine Cuevas-MotaKelly CollinsFatima MuñozDonald G. CatanzaroKathleen MoserJulie HigashiTeeb Al-SamarraiPaula KrinerJulie VaishampayanJavier CepedaMichelle A. BulterysNatasha K. MartinPhillip RiosFredric RaabWe assessed video directly observed therapy (VDOT) for monitoring tuberculosis treatment in 5 health districts in California, USA, to compare adherence between 274 patients using VDOT and 159 patients using in-person directly observed therapy (DOT). Multivariable linear regression analyses identified participant-reported sociodemographics, risk behaviors, and treatment experience associated with adherence. Median participant age was 44 (range 18–87) years; 61% of participants were male. Median fraction of expected doses observed (FEDO) among VDOT participants was higher (93.0% [interquartile range (IQR) 83.4%–97.1%]) than among patients receiving DOT (66.4% [IQR 55.1%–89.3%]). Most participants (96%) would recommend VDOT to others; 90% preferred VDOT over DOT. Lower FEDO was independently associated with US or Mexico birth, shorter VDOT duration, finding VDOT difficult, frequently taking medications while away from home, and having video-recording problems (p<0.05). VDOT cost 32% (range 6%–46%) less than DOT. VDOT was feasible, acceptable, and achieved high adherence at lower cost than DOT.https://wwwnc.cdc.gov/eid/article/24/10/18-0459_articlemHealthmedication adherence monitoringsmartphonevideo technologyantimicrobial resistancepatient-centered care |
| spellingShingle | Richard S. Garfein Lin Liu Jazmine Cuevas-Mota Kelly Collins Fatima Muñoz Donald G. Catanzaro Kathleen Moser Julie Higashi Teeb Al-Samarrai Paula Kriner Julie Vaishampayan Javier Cepeda Michelle A. Bulterys Natasha K. Martin Phillip Rios Fredric Raab Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA Emerging Infectious Diseases mHealth medication adherence monitoring smartphone video technology antimicrobial resistance patient-centered care |
| title | Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA |
| title_full | Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA |
| title_fullStr | Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA |
| title_full_unstemmed | Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA |
| title_short | Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA |
| title_sort | tuberculosis treatment monitoring by video directly observed therapy in 5 health districts california usa |
| topic | mHealth medication adherence monitoring smartphone video technology antimicrobial resistance patient-centered care |
| url | https://wwwnc.cdc.gov/eid/article/24/10/18-0459_article |
| work_keys_str_mv | AT richardsgarfein tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT linliu tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT jazminecuevasmota tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT kellycollins tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT fatimamunoz tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT donaldgcatanzaro tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT kathleenmoser tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT juliehigashi tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT teebalsamarrai tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT paulakriner tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT julievaishampayan tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT javiercepeda tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT michelleabulterys tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT natashakmartin tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT philliprios tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT fredricraab tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa |